Why Ligand Pharmaceuticals Incorporated (LGND) stock moved
Ligand Pharmaceuticals Incorporated (LGND) shares rose 4.2% to $314.10 as of September 28, 2026, a moderate gain from the prior close of $301.52. BestStocks flagged the session as a major change for LGND. Below, we break down what changed for LGND, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
LGND climbed 4.2% to $314.10
LGND rose 4.2% in its latest session, moving from $301.52 to $314.10.
What it means for Ligand Pharmaceuticals Incorporated investors
For Ligand Pharmaceuticals Incorporated investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 4.2% session move. Weighing against that: Ligand Pharmaceuticals Incorporated (LGND) moved -3.69% from $304.37 to $293.15 on 2026-08-07; Ligand Pharmaceuticals Incorporated (LGND) moved -3.10% from $303.39 to $293.99 on 2026-07-20. Wall Street's consensus price target sits at $339.43, implying +8.1% upside from $314.10. BestStocks rates the overall signal quality low (52/100). With earnings roughly 38 days out, the next report is the most likely near-term test of the move.
LGND price reaction
LGND last traded at $314.10, up $12.58 (+4.17%) from the previous close of $301.52. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $275.20 and $314.10, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Ligand Pharmaceuticals Incorporated (LGND)
The consensus analyst price target on Ligand Pharmaceuticals Incorporated (LGND) is $339.43, 8.1% above the recent $314.10. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LGND line up.
The bullish case
- Wall Street's consensus price target of $339.43 implies +8.1% upside from $314.10.
- The Street's most bullish target is $358.00 (+14.0%).
- Material positive event.
- Positive 4.2% session move.
- Positive price momentum.
The bearish case
- Ligand Pharmaceuticals Incorporated (LGND) moved -3.69% from $304.37 to $293.15 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 28, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LGND
Frequently asked questions about LGND
Why did Ligand Pharmaceuticals Incorporated (LGND) stock move?
LGND rose 4.2% to $314.10. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did LGND stock rise?
LGND gained 4.17% ($12.58) versus the prior close of $301.52, last trading at $314.10 on 0.8× average volume.
When is Ligand Pharmaceuticals Incorporated's next earnings date?
LGND's next earnings report is estimated for 2026-11-05 — about 38 days away.
What is the analyst price target for LGND?
The consensus analyst price target for LGND is $339.43, about 8.1% above the current $314.10. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.
How BestStocks tracks LGND
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LGND-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for LGND, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 28, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.